Yangtze River Pharmaceutical (Group) Co., Ltd.

Yangtze River Pharmaceutical Group (YRPG) is a large-scale, cross-region Chinese pharmaceutical group founded in 1971. As of July 2019, with a total area exceeding 3 million square meters, YRPG owns 14 manufacturing subsidiaries located in Beijing, Shanghai, Nanjing, Guangzhou and elsewhere, having established R&D and production bases for innovative chemical medicine, patent traditional Chinese medicine (TCM) and biological medicines. Four workshops, six FDFs and one NEX have been EU GMP certified, including Enalapril Maleate Tablets, Omeprazole Enteric-Coated Capsules, Nifedipine Prolonged Release Tablets, Glimepiride Tablets, Sotalol Hydrochloride Tablets, Ginkgo Biloba Tablets and Ginkgo Biloba Extract; Omeprazole Capsules were exported to Germany in 2012, and 79 FDFs have been exported to 25 countries/regions across Europe, Asia and Africa. From 2012 to 2018, YRPG was ranked No. 1 among the Top 100 Enterprises in China's chemical pharmaceutical industry.